Intravenous and sublingual buprenorphine in horses: Pharmacokinetics and influence of sampling site

Veterinary Anaesthesia and Analgesia

Volumn 38, Issue 4, 2011, Pages 374-384

  Messenger, Kristen M ^a   Davis, Jennifer L ^a   Lafevers, Douglas H ^a   Barlow, Beth M ^a   Posner, Lysa P ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Analgesia; Buprenorphine; Equine; Opioids; Pharmacokinetics; Sampling site

Indexed keywords

ANIMALIA; EQUIDAE;

EID: 79958791141     PISSN: 14672987     EISSN: 14672995     Source Type: Journal    
DOI: 10.1111/j.1467-2995.2011.00613.x     Document Type: Article

References (32)

1. Abbo LA, Ko JC, Maxwell LK et al. (2008) Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs. Vet Ther 9, 83-93.
2. Bennett RC, Steffey EP (2002) Use of opioids for pain and anesthetic management in horses. Vet Clin North Am Equine Pract 18, 47-60.
3. Boscan P, Van Hoogmoed LM, Pypendop BH et al. (2006) Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. Am J Vet Res 67, 998-1004.
4. Briggs SL, Sneed K, Sawyer DC (1998) Antinociceptive effects of oxymorphone-butorphanol-acepromazine combination in cats. Vet Surg 27, 466-472.
5. Carregaro AB, Neto FJT, Beier SL et al. (2006) Cardiopulmonary effects of buprenorphine in horses. Am J Vet Res 67, 1675-1680.
6. Carregaro AB, Luna SP, Mataqueiro MI et al. (2007) Effects of buprenorphine on nociception and spontaneous locomotor activity in horses. Am J Vet Res 68, 246-250.
7. Combie JD, Nugent TE, Tobin T (1983) Pharmacokinetics and protein binding of morphine in horses. Am J Vet Res 44, 870-874.
8. Cowan A, Lewis JW, MacFarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmac 60, 537-545.
9. Huang P, Kehner GB, Cowan A et al. (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297, 688-695.
10. Hubbell JA, Muir WW (1996) Evaluation of a survey of the diplomates of the American College of Laboratory Animal Medicine on use of analgesic agents in animals used in biomedical research. J Am Vet Med Assoc 209, 918-921.
11. Jensen ML, Foster D, Upton R et al. (2007) Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica 37, 441-457.
12. Kaukinen H, Aspergren J, Hyyppa S et al. (2011) Bioavailability of detomidine administered sublingually to horses as an oromucosal gel. J Vet Pharmacol Therap 34, 76-81.
13. Ko JC, Freeman LJ, Barletta M et al. (2011) Efficacy of oral transmucosal and intravenous administration of buprenorphine before surgery for postoperative analgesia in dogs undergoing ovariohysterectomy. J Am Vet Med Assoc 238, 318-328.
14. Krotscheck U, Boothe DM, Little AA (2008) Pharmacokinetics of buprenorphine following intravenous administration in dogs. Am J Vet Res 69, 722-727.
15. Kuhlman JJ, Lalani S, Magluilo J Jr et al. (1996) Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 20, 369-378.
16. Love EJ, Murrell J, Whay HR et al. (2008) Antinociceptive effects of buprenorphine in horses: a dose finding study. Proceedings of the Annual Meeting of the American College of Veterinary Anesthesiologists, Scottsdale, AZ. (Abstract).
17. Love EJ, Pelligand L, Sear J et al. (2010) Pharmacokinetics of intravenous buprenorphine in conscious horses. Vet Anaesth Analg 37, 11 (Abstract).
18. Lufty K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2, 395-402.
19. Maxwell LK, Thomasy SM, Slovis N et al. (2003) Pharmacokinetics of fentanyl following intravenous and transdermal administration in horses. Equine Vet J 35, 484-490.
20. McInnes F, Clear N, James G et al. (2008) Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. Pharm Res 25, 869-874.
21. Nolan A, Livingston A, Waterman AE (1987) Investigation of the antinociceptive activity of buprenorphine in sheep. Br J Pharmac 92, 527-533.
22. Ohtani M, Kotaki H, Sawada Y et al. (1995) Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272, 505-510.
23. Pascoe PJ, Taylor PM (2003) Effects of dopamine antagonists on alfentanil-induced locomotor activity in horses. Vet Anaesth Analg 30, 165-171.
24. Potani RB, Vadlamani NL, Misra AL (1985) Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 15, 287-297.
25. Robertson SA, Lascelles BDX, Taylor PM et al. (2005) PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. J Vet Pharmacol Therap 28, 453-460.
26. Sellon DC, Monroe VL, Roberts MC et al. (2001) Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses. Am J Vet Res 62, 183-189.
27. Taylor PM, Robertson SA, Dixon MJ et al. (2001) Morphine, pethidine, and buprenorphine disposition in the cat. J Vet Pharmacol Therap 24, 391-398.
28. Tuk B, Danhof M, Mandema JW (1997) The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J Pharmacokinet Biopharm 25, 39-62.
29. Walker AF (2007) Sublingual administration of buprenorphine for long-term analgesia in the horse. Vet Rec 160, 808-809.
30. Watson PJ, McQuay HJ, Bullingham RE et al. (1982) Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clinical effects and plasma concentration. Br J Anaesth 54, 37-43.
31. Weinberg DS, Inturrisi CE, Reidenberg B et al. (1988) Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44, 335-342.
32. Yassen A, Olafson E, Dahan A et al. (2005) Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 313, 1136-1149.